Moreover, using IHC, we found that p53 and p16 expression could be used as surrogate marker for TP53 and CDKN2A mutational status, respectively, and aberrant expression of p53 and/or p16 could be a predictive marker of malignant transformation of IP. The gene discussed is TP53; the disease is incontinentia pigmenti.